Company to host conference call and webcast on Thursday, November 19 at 8:30 am EDT LYON, France , November 9, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the third quarter ended September 30, 2020
Call to be Held Tuesday, September 22 nd @ 8am Eastern Time LYON, France , September 15, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will host a key opinion leader (KOL) call on its two lead commercial products, Focal One ® and
LYON, France , September 9, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the HC Wainwright Virtual 22nd Annual Global Investment Conference , which is being held September 14-15, 2020 . Presentation
· First patients already treated as recruitment accelerates LYON, France , September 3, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first two patients have been treated in the company’s Phase 2 clinical trial assessing
Completed multiple Focal One sales to renowned U.S. and international health care institutions, including multiple Focal One™-ExactVu™ bundled sales Announced first two U.S. publications in Journal of Urology detailing positive outcomes from U.S. studies of HIFU for the successful partial-gland
Multicenter study to commence in September in France Reinforces company’s recent shift in strategic focus toward development of additional high-value HIFU tissue ablation indications LYON, France , August 25, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic
Company to host conference call and webcast on Thursday, August 27 at 8:30 am EDT LYON, France , August 19, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the second quarter ended June 30, 2020 after the
Studies conducted at the University of Southern California and University of Miami represent the first U.S. publications detailing successful partial-gland ablation using high intensity focused ultrasound therapy to treat prostate cancer patients since FDA cleared the technology in 2015.
Company completes four Focal One sales, including three bundled sales that combine Focal One® with Exact Imaging’s ExactVu micro ultrasound imaging solution Company recorded an additional three stand-alone ExactVu purchase orders at major centers LYON, France , July 15, 2020 -- EDAP TMS SA (Nasdaq:
Appointment adds significant medical technology executive and board leadership experience LYON, France , June 30, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, announced today that veteran medical technology executive Marie Meynadier has